Three human term placentas have been perfused in situ with labeled pregnenolone.
The rapid and extensive in situ conversion of --labeled pregnenolone') to progesterone in the midterm human placenta has been demonstrated (1) . The capacity for enzyme nmaturation' in various human fetal and infant tissues both with advancing gestation and during the neonatal period has also been suggested (2, 3) .
The following experiment was designed in an effort to assess the qualitative and quantitative aspects of in vivo human placental steroidogenesis at term --utilizing pregnenolone as substrate, as well as to develop a satisfactory model for the study of in situ --steroidogenesis in the human term placenta utilizing 8:l a variety of substrates.
METHODS AND MATERIALS
Perfusion Technique: Studies were carried out on three patients scheduled for elective repeat cesarean section at term, with no other medical or obstetric complication of the present pregnancy.
Under tetracaine hydrochloride spinal anesthesia, following delivery of the infant by cesarean section, a sterile infant feeding tube was inserted into one umbilical artery and an adult feeding tube into the umbilical vein.
Citrated whole blood, typed and cross-matched against that of the mother, was infused into the umbilical arterial catheter.
At one minute intervals, over a period of 7 minutes, 0.1 ml of a 50% ethanol in distilled water (v/v) solution of isotopic pregnenolone was injected into the arterial catheter. This was followed by 2 minutes of additional blood perfusion without further injection of steroid.
The venous effluent was collected in a flask of absolute ethanol.
Materials:
All organic solvents were redistilled prior to use.
Crystalline steroid standards were recrystallized prior to use and corrected melting points determined.
Pregnenolone-7a-3H, Lot No. 66-156A-lg2) with a specific activity (S-A.) of 31.6 mc/mg and pregnenolone-4-14C, Lot No. 79-239A-402) with a S.A. of 14.5 mc/mg were purified utilizing thin-layer chromatography on Silica gel G3) in the following solvent systems:
cyclohexane: ethyl acetate: ethanol, 9: 9: 2 (Rf = 0.57) and benzene: ethanol, 9: 1 (Rf = 0.38). An aliquot of this purified material was then mixed with authentic carrier and recrystallized from ethanol and methanol.
Initial recrystallization demonstrated agreement within 5% of that of the specific activity of the starting material.
The amount of pregnenolone-7a-3H perfused (Experiments 1 and 2) was 5.0 and 5.8 uc, and that of pregnenolone-4-14c (Experiment 3) was 2.0 WC.
Extraction and Purification:
The umbilical venous effluent was collected dropwise in 200 ml of ethanol, which was constantly agitated.
After completion of the perfusion, the placenta was manually removed, membranes and cord immediately dissected away and the placenta homogenized in 400 ml of ethanol. Further extraction with ethanol, and methanol precipitation were carried out as described by Mikhail et al. (4) .
Separation of "free" from "conjugated" radioactive material was carried out in a countercurrent fashion using a dichloromethane-water partition, with three separatory funnels and six lower-phase transfers. The volume of each phase was 50 ml.
An outline of the extraction and identification procedures employed on the dichloromethane fraction is shown in Figure 1 .
Twenty-four hour urine specimens were collected for three days following the procedure, and aliquots of each days urine assessed for their radioactive content. 
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Estimation of C-21 Steroids:
The 01, B-unsaturated 3-ketosteroids were detected on thin-layer chromatograms by ultraviolet light and measured by ultraviolet absorption at 240 rnp using the Allen correction formula (7). For detection of 3@-hydroxy-A5-steroids on thin-layer chromatograms, a phosphomolybdic acid spray was employed, and their measurement was carried out by the method of Oertel and Eik-Nes (8).
Recrystallization to Constant Specific Activity: Appropriate carrier steroid was added to the isolated radioactive material derived from the final countercurrent distribution.
For each isolated compound, successive recrystallizations from at least three different solvent systems were performed.
The carrier was estimated gravimetrically.
Countinq Procedure:
Counting was carried out in an automated two channel Packard Tri-Carb liquid scintillation counter (series 3000). The tritium window was set from 10 to 100% of the analyzer full scale with a relative gain of 60, and the carbon window was set from 10 to 70% of full scale with a relative gain of 5. Samples were counted in 10 ml toluene containing 3.0 g/l PPO (2,5_diphenyloxazole) and 100 mg/l POPOP (1, 4-bis-2-(4-methyl-5-phenyloxazolyl) benzene).
Urine samples (0.5 ml) were first dissolved in one ml methanol and then 10 ml of the above toluene scintillant solution added. Appropriate quench corrections were performed using an internal standard technique.
Counting efficiencies were monitored utilizing standards prepared in the same manner as the samples.
RESULTS
As seen in Table 1 , 47.7 to 66.3 percent of the perfused radioactivity was recovered from the three sources in which it was measured. As noted in Fig. 1 Table 4 .
Additionally, as seen in Fig. 1 The term placenta also has the capacity of converting circulating cholesterol to pregnenolone (9) .
In addition, there is extensive desulfurylation of pregnenolone sulfate, perfused in situ to the human --term placenta (lo), and conversion of the bulk of the pregnenolone so formed to progesterone. Thus the relative contribution to placental progesterone production by 1) pregnenolone produced in the placenta from circulating cholesterol, 2) circulating pregnenolone sulfate (which has been demonstrated in both pooled peripheral plasma (11) and umbilical cord blood (12) and 3) "free" circulating pregnenolone (which could not be found in umbilical cord blood although free 17c-hydroxypregnenolone was detected (12)), remains to be ascertained.
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